BioStock: BioInvent focus on first line treatment
Refinitiv閱讀少於1分鐘
BioInvent’s phase I dose escalation study of BI-1206, combined with MSD’s pembrolizumab, showed promising clinical activity in heavily pre-treated patients with advanced solid tumors. With a phase IIa study planned for treatment-naive NSCLC and uveal melanoma patients in H2 2025, we contacted CMO Andres McAllister for comment.
Read the full interview at biostock.se:
https://biostock.se/en/2025/06/bioinvent-focus-on-first-line-treatment/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
登入或建立一個永久免費帳戶來閱讀此新聞